WO2011147425A1 - Procédé et dispositif de mesure et de surveillance des concentrations de substances dans un liquide biologique - Google Patents
Procédé et dispositif de mesure et de surveillance des concentrations de substances dans un liquide biologique Download PDFInfo
- Publication number
- WO2011147425A1 WO2011147425A1 PCT/EE2011/000005 EE2011000005W WO2011147425A1 WO 2011147425 A1 WO2011147425 A1 WO 2011147425A1 EE 2011000005 W EE2011000005 W EE 2011000005W WO 2011147425 A1 WO2011147425 A1 WO 2011147425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- concentration
- biological fluid
- substances
- dialysis
- sample
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 176
- 239000000126 substance Substances 0.000 title claims abstract description 58
- 239000013060 biological fluid Substances 0.000 title claims abstract description 51
- 238000012544 monitoring process Methods 0.000 title claims abstract description 23
- 238000000502 dialysis Methods 0.000 claims abstract description 98
- 230000003287 optical effect Effects 0.000 claims abstract description 52
- 230000014759 maintenance of location Effects 0.000 claims abstract description 32
- 238000005259 measurement Methods 0.000 claims abstract description 27
- 230000001131 transforming effect Effects 0.000 claims abstract description 16
- 230000003595 spectral effect Effects 0.000 claims abstract description 14
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 12
- 238000012552 review Methods 0.000 claims abstract description 11
- 238000001228 spectrum Methods 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 238000004364 calculation method Methods 0.000 claims abstract description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 88
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 73
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 73
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 73
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 64
- 229940116269 uric acid Drugs 0.000 claims description 64
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 59
- 238000002835 absorbance Methods 0.000 claims description 55
- 239000004202 carbamide Substances 0.000 claims description 49
- 229940109239 creatinine Drugs 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 11
- 229940045136 urea Drugs 0.000 claims description 10
- 238000013507 mapping Methods 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 6
- 235000003715 nutritional status Nutrition 0.000 claims description 6
- 238000011481 absorbance measurement Methods 0.000 claims description 4
- 238000013079 data visualisation Methods 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 4
- 208000028208 end stage renal disease Diseases 0.000 abstract description 3
- 201000000523 end stage renal failure Diseases 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 238000010200 validation analysis Methods 0.000 description 16
- 239000002441 uremic toxin Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 238000001631 haemodialysis Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000322 hemodialysis Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000005569 Gout Diseases 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 108010046334 Urease Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003339 best practice Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000005518 electrochemistry Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 238000010989 Bland-Altman Methods 0.000 description 1
- 206010005133 Bleeding tendencies Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010077078 Creatinase Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 101710128029 Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 238000007375 Jaffe assay Methods 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 1
- 102000008118 Sarcosine oxidase Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940000032 cardiovascular system drug Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000010978 in-process monitoring Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000001008 quinone-imine dye Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000010248 tubular secretion Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/85—Investigating moving fluids or granular solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/01—Arrangements or apparatus for facilitating the optical investigation
- G01N21/03—Cuvette constructions
- G01N21/05—Flow-through cuvettes
Abstract
L'invention concerne un procédé et un dispositif de surveillance de l'élimination de solutés de rétention urémique difficilement ou facilement diffusibles au cours de la dialyse et de mesure des concentrations desdites substances dans un liquide biologique et, plus spécifiquement, dans le dialysat sortant, afin d'estimer la dose de dialyse sur des patients en cours de dialyse. Des mesures sont réalisées de manière optique à l'aide du spectre du liquide biologique et un algorithme de calcul de concentrations contenant la fonction de transformation, comprenant un ensemble unique de composantes du spectre optique à certaines longueurs d'onde, afin de déterminer la concentration des substances dans des échantillons in vitro ou des liquides s'écoulant, en direct. Le procédé et le dispositif déterminent la concentration des substances in vitro ou en direct à l'aide d'une cuve de mesure adaptée pour des mesures spécifiées. Ceci permet la surveillance quantitative des concentrations des substances dans un liquide biologique et le calcul de la dose de dialyse pour des solutés de rétention urémique difficilement ou facilement diffusibles, adaptée pour surveiller automatiquement et rapidement la qualité de la dialyse administrée aux patients atteints d'une maladie rénale en stade terminal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20110741089 EP2577270A1 (fr) | 2010-05-27 | 2011-05-27 | Procédé et dispositif de mesure et de surveillance des concentrations de substances dans un liquide biologique |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EEP201000049 | 2010-05-27 | ||
| EEP201000049A EE05674B1 (et) | 2010-05-27 | 2010-05-27 | Seade ja meetod vikese molekulmassiga veeslahustuvate ainete uurea, kreatiniini ja kusihappe kontsentratsiooni kvantitatiivseks mramiseks |
| EEP201100002 | 2011-01-14 | ||
| EEP201100002A EE05637B1 (et) | 2011-01-14 | 2011-01-14 | Meetod ja seade raskesti difundeeruvate ureemiliste retentsiooni soluutide kontsentratsioonide mramiseks bioloogilises vedelikus ja nende eemaldamise monitooringuks UV-neelduvusega neeruasendusravil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011147425A1 true WO2011147425A1 (fr) | 2011-12-01 |
Family
ID=44484872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EE2011/000005 WO2011147425A1 (fr) | 2010-05-27 | 2011-05-27 | Procédé et dispositif de mesure et de surveillance des concentrations de substances dans un liquide biologique |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2577270A1 (fr) |
| WO (1) | WO2011147425A1 (fr) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012152514A1 (fr) | 2011-05-11 | 2012-11-15 | Ldiamon As | Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine |
| RU2499557C1 (ru) * | 2012-10-08 | 2013-11-27 | Арсений Юрьевич Шитов | Способ оценки волюморегулирующей функции почек в условиях повышенного давления газовой среды |
| DE102012112790A1 (de) * | 2012-12-20 | 2014-06-26 | B. Braun Avitum Ag | Verfahren und Vorrichtung zur Bestimmung von Abfallprodukten wie Indoxyl Sulfate in der Dialyse |
| RU2525738C1 (ru) * | 2013-04-09 | 2014-08-20 | Арсений Юрьевич Шитов | Способ оценки кальцийуретической функции почек человека в условиях повышенного давления газовой среды |
| DE102014106489A1 (de) * | 2014-05-08 | 2015-11-12 | B. Braun Avitum Ag | Vorrichtung und Vorrichtungs-Steuerungsverfahren zur quantitativen Konzentrationsbestimmung ausgewählter aus einem Patientenkörper ausgefilterter Substanzen in einer Flüssigkeit |
| CN105823746A (zh) * | 2016-05-23 | 2016-08-03 | 青岛海大生物集团有限公司 | 一种水溶肥料中壳聚糖含量的检测方法 |
| RU2709469C1 (ru) * | 2019-10-03 | 2019-12-18 | Арсений Юрьевич Шитов | Способ определения степени индивидуальной устойчивости водолазов к токсическому действию азота по показателям функций почек |
| RU2709477C1 (ru) * | 2019-10-03 | 2019-12-18 | Арсений Юрьевич Шитов | Способ определения степени индивидуальной устойчивости водолазов к токсическому действию кислорода по показателям функций почек |
| WO2020182395A1 (fr) | 2019-03-11 | 2020-09-17 | Gambro Lundia Ab | Estimation du taux de génération d'une substance chez des patients sous dialyse |
| CN112805044A (zh) * | 2018-08-23 | 2021-05-14 | 尼普洛株式会社 | 细胞外液量计算装置和细胞外液量计算方法 |
| US11255844B2 (en) | 2018-03-06 | 2022-02-22 | Fresenius Medical Care Holdings, Inc. | Peritoneal dialysis systems and related methods |
| WO2022172059A1 (fr) * | 2021-02-12 | 2022-08-18 | AusMed Global Limited | Système et procédé de détermination d'une concentration d'un analyte dans un fluide |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5357960A (en) | 1988-10-07 | 1994-10-25 | Siemens Aktiengesellschaft | Method and apparatus for the quantitative determination of optically active substances |
| WO1998019592A1 (fr) | 1996-11-01 | 1998-05-14 | Rio Grande Medical Technologies, Inc. | Procede et dispositif de surveillance de dialyse |
| US5886347A (en) | 1994-07-13 | 1999-03-23 | Horiba, Ltd. | Analytical method for multi-component aqueous solutions and apparatus for the same |
| WO1999062574A1 (fr) | 1998-06-04 | 1999-12-09 | Althin Medical Ab | Procede permettant de determiner la quantite de dechets dans le liquide de dialyse au cours d'une dialyse |
| US6121050A (en) | 1997-08-29 | 2000-09-19 | Han; Chi-Neng Arthur | Analyte detection systems |
| RU2212029C1 (ru) | 2001-12-03 | 2003-09-10 | Общество с ограниченной ответственностью "Клиника экстракорпоральной гемокоррекции" | Способ анализа жидкой биологической среды в процессе мониторинга |
| US20030231294A1 (en) * | 2002-06-12 | 2003-12-18 | Ramesh Wariar | Optical sensor and method for measuring concentration of a chemical constituent using its intrinsic optical absorbance |
| US20070023334A1 (en) | 2003-09-23 | 2007-02-01 | Gambro Lundia Ab | Apparatus, a system and a method relating to hemodialysis, hemodiafiltration, hemofiltration or peritoneal dialysis |
| US7372039B2 (en) | 2005-12-20 | 2008-05-13 | Ecolab Inc. | Near UV absorption spectrometer and method for using the same |
| EP1070954B1 (fr) | 1999-07-20 | 2008-11-05 | Secomam | Procédé et dispositif pour l'analyse d'un échantillon liquide. |
| US20080304048A1 (en) | 2005-11-29 | 2008-12-11 | Ge Healthcare Bio-Sciences Ab | Methods and Apparatus For Measuring the Concentration of a Substance in a Solution |
| EP2005982A1 (fr) | 2007-06-20 | 2008-12-24 | B. Braun Avitum AG | Procédé pour déterminer le rapport de réduction ou la valeur Kt/V d'un traitement de remplacement de rein et appareil pour la mise en place du procédé |
| WO2009071102A1 (fr) | 2007-12-04 | 2009-06-11 | Tallinn University Of Technology | Procédé et dispositif optique pour mesurer des concentrations de substances dans des fluides biologiques |
| US20110040494A1 (en) | 2007-11-26 | 2011-02-17 | Kevin Anthony Foster | Method and apparatus for absorption spectra analysis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010034626A1 (de) * | 2010-08-17 | 2012-02-23 | B. Braun Avitum Ag | Vorrichtung zur extrakorporalen Blutbehandlung |
-
2011
- 2011-05-27 WO PCT/EE2011/000005 patent/WO2011147425A1/fr active Application Filing
- 2011-05-27 EP EP20110741089 patent/EP2577270A1/fr not_active Withdrawn
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5357960A (en) | 1988-10-07 | 1994-10-25 | Siemens Aktiengesellschaft | Method and apparatus for the quantitative determination of optically active substances |
| US5886347A (en) | 1994-07-13 | 1999-03-23 | Horiba, Ltd. | Analytical method for multi-component aqueous solutions and apparatus for the same |
| WO1998019592A1 (fr) | 1996-11-01 | 1998-05-14 | Rio Grande Medical Technologies, Inc. | Procede et dispositif de surveillance de dialyse |
| US6121050A (en) | 1997-08-29 | 2000-09-19 | Han; Chi-Neng Arthur | Analyte detection systems |
| WO1999062574A1 (fr) | 1998-06-04 | 1999-12-09 | Althin Medical Ab | Procede permettant de determiner la quantite de dechets dans le liquide de dialyse au cours d'une dialyse |
| US6666840B1 (en) | 1998-06-04 | 2003-12-23 | Althin Medical Ab | Method for determining waste products in the dialysis liquid in dialysis treatment |
| EP1070954B1 (fr) | 1999-07-20 | 2008-11-05 | Secomam | Procédé et dispositif pour l'analyse d'un échantillon liquide. |
| RU2212029C1 (ru) | 2001-12-03 | 2003-09-10 | Общество с ограниченной ответственностью "Клиника экстракорпоральной гемокоррекции" | Способ анализа жидкой биологической среды в процессе мониторинга |
| US20030231294A1 (en) * | 2002-06-12 | 2003-12-18 | Ramesh Wariar | Optical sensor and method for measuring concentration of a chemical constituent using its intrinsic optical absorbance |
| US20070023334A1 (en) | 2003-09-23 | 2007-02-01 | Gambro Lundia Ab | Apparatus, a system and a method relating to hemodialysis, hemodiafiltration, hemofiltration or peritoneal dialysis |
| US20080304048A1 (en) | 2005-11-29 | 2008-12-11 | Ge Healthcare Bio-Sciences Ab | Methods and Apparatus For Measuring the Concentration of a Substance in a Solution |
| US7372039B2 (en) | 2005-12-20 | 2008-05-13 | Ecolab Inc. | Near UV absorption spectrometer and method for using the same |
| EP2005982A1 (fr) | 2007-06-20 | 2008-12-24 | B. Braun Avitum AG | Procédé pour déterminer le rapport de réduction ou la valeur Kt/V d'un traitement de remplacement de rein et appareil pour la mise en place du procédé |
| US20110040494A1 (en) | 2007-11-26 | 2011-02-17 | Kevin Anthony Foster | Method and apparatus for absorption spectra analysis |
| WO2009071102A1 (fr) | 2007-12-04 | 2009-06-11 | Tallinn University Of Technology | Procédé et dispositif optique pour mesurer des concentrations de substances dans des fluides biologiques |
Non-Patent Citations (25)
| Title |
|---|
| ARTISS, J. D., R. E. KARCHER ET AL.: "Application and evaluation of a new cold- stable kinetic Jaffe reagent to the Hitachi 747 for the determination of serum creatinine", MICROCHEMICAL JOURNAL, vol. 65, no. 3, 2000, pages 277 - 282 |
| CANO F ET AL: "Kt/V and nPNA in pediatric peritoneal dialysis: a clinical or a mathematical association?", PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER, BERLIN, DE, vol. 21, no. 1, 1 January 2006 (2006-01-01), pages 114 - 118, XP019347992, ISSN: 1432-198X, DOI: 10.1007/S00467-005-2048-9 * |
| CASINO FG, PEDRINI LA, SANTORO A, MANDOLFO S, DAVID S, DE CRISTOFARO V, TEATINI U, LOMONTE C, LOPEZ T: "A simple approach for assessing equilibrated Kt/V beta 2-M on a routine basis", NEPHROL DIAL TRANSPLANT., vol. 25, no. 9, September 2010 (2010-09-01), pages 3038 - 44 |
| CHEUNG AK, GREENE T, LEYPOLDT JK, YAN G, ALLON M, DELMEZ J, LEVEY AS, LEVIN NW, ROCCO MV, SCHULMAN G: "HEMO Study Group. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients", CLIN J AM SOC NEPHROL., vol. 3, no. 1, January 2008 (2008-01-01), pages 69 - 77 |
| CHEUNG AK, ROCCO MV, YAN G, LEYPOLDT JK, LEVIN NW, GREENE T, AGODOA L, BAILEY J, BECK GJ, CLARK W: "Serum -2 microglobulin levels predict mortality in dialysis patients: results of the HEMO Study", J AM SOC NEPHROL, vol. 17, no. 2, February 2006 (2006-02-01), pages 546 - 55 |
| DE SMET R, GLORIEUX G, HSU C, VANHOLDER R: "P-cresol and uric acid: two old uremic toxins revisited", KIDNEY INT, vol. 62, November 1997 (1997-11-01), pages 8 - 11 |
| DHONDT, A. W., R. C. VANHOLDER ET AL.: "Studies on dialysate mixing in the Genius (R) single-pass batch system for hemodialysis therapy", KIDNEY INTERNATIONAL, vol. 63, no. 4, 2003, pages 1540 - 1547 |
| DRUEKE TB, MASSY ZA: "Beta2-microglobulin", SEMIN DIAL., vol. 22, no. 4, July 2009 (2009-07-01), pages 378 - 80 |
| ERA-EDTA: "EBPG - European Best Practice Guidelines: SECTION II. Haemodialysis adequacy 11.2 Haemodialysis dose quantification: middle molecules (MM", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 17, no. 7, 2002, pages 21 - 23 |
| FEIG DI, KANG DH, JOHNSON RJ: "Uric acid and cardiovascular risk", N ENGL J MED., vol. 359, no. 17, 23 October 2008 (2008-10-23), pages 1811 - 21 |
| FRIDOLIN I ET AL: "ON-LINE MONITORING OF SOLUTES IN DIALYSATE USING WAVELENGTH-DEPENDENT ABSORPTION OF ULTRAVIOLET RADIATION", MEDICAL AND BIOLOGICAL ENGINEERING AND COMPUTING, SPRINGER, HEILDELBERG, DE, vol. 41, no. 3, 1 May 2003 (2003-05-01), pages 263 - 270, XP001047249, ISSN: 0140-0118, DOI: 10.1007/BF02348430 * |
| FRIDOLIN, I., M. MAGNUSSON ET AL.: "On-line monitoring of solutes in dialysate using absorption of ultraviolet radiation: technique description", THE INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, vol. 25, no. 8, 2002, pages 748 - 761, XP008101248 |
| HAYDEN MR, TYAGI SC: "Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle (review", NUTR METAB (LOND, vol. 1, no. 1, 19 October 2004 (2004-10-19), pages 10, XP021010947, DOI: doi:10.1186/1743-7075-1-10 |
| HOIEGGEN A, ALDERMAN MH, KJELDSEN SE ET AL.: "LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study", KIDNEY INT., vol. 65, no. 3, March 2004 (2004-03-01), pages 1041 - 9 |
| LUMAN, M., J. JEROTSKAJA ET AL.: "Dialysis dose and nutrition assessment by optical on-line dialysis adequacy monitor", CLINICAL NEPHROLOGY, vol. 72, no. 4, 2009, pages 303 - 311, XP009151764 |
| NAKAGAWA T, MAZZALI M, KANG D-H, SANCHEZ-LOZADA LG, HERRERA-ACOSTA J, JOHNSON RJ: "Uric acid- a uremic toxin?", BLOOD PURIF., vol. 24, 2006, pages 67 - 70 |
| NAVANEETHAN SD, BEDDHU S: "Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease", NEPHROL DIAL TRANSPLANT., vol. 24, no. 4, April 2009 (2009-04-01), pages 1260 - 66 |
| PERLSTEIN T S, GUMIENIAK 0, HOPKINS P, MURPHEY L, BROWN N, WILLIAMS G: "Uric acid and the state of intrarenal renin-angiotensin system in humans", KIDNEY INT, vol. 66, 2004, pages 1465 - 1470 |
| See also references of EP2577270A1 * |
| UHLIN, F., I. FRIDOLIN ET AL.: "Estimating total urea removal and protein catabolic rate by monitoring UV absorbance in spent dialysate", NEPHROL DIAL TRANSPLANT., 20 November 2005 (2005-11-20), pages 2458 - 2464, XP001167226, DOI: doi:10.1093/NDT/GFI026 |
| UHLIN, F., I. FRIDOLIN ET AL.: "Estimation of delivered dialysis dose by on-line monitoring of the UV-absorbance in the spent dialysate", AMERICAN JOURNAL OF KIDNEY DISEASES, vol. 41, 5 May 2003 (2003-05-05), pages 1026 - 1036, XP028836390, DOI: doi:10.1016/S0272-6386(03)00200-2 |
| UHLIN, F., L. G. LINDBERG ET AL.: "Total Removed Uric Acid During Dialysis Estimated by On-line Ultra Violet Absorbance in the Spent Dialysate", 3RD EUROPEAN MEDICAL & BIOLOGICAL ENGINEERING CONFERENCE, EMBEC'05, PRAGUE, CZECH REPUBLIC, IFMBE PROCEEDINGS, vol. 11, 2005, pages 6 |
| VANHOLDER, R., R. DE SMET ET AL.: "Review on uremic toxins: classification, concentration, and interindividual variability", KIDNEY INTERNATIONAL, vol. 63, no. 5, 2003, pages 1934 - 1943, XP009088717, DOI: doi:10.1046/j.1523-1755.2003.00924.x |
| VIAZZI F, LEONCINI G, RATTO E, PONTREMOLI R: "Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived", J CLIN HYPERTENS, vol. 8, no. 7, 2006, pages 510 - 518 |
| YAVUZ, A. ET AL.: "Uremic toxins: a new focus on an old subject", SEMIN DIAL, vol. 18, no. 3, May 2005 (2005-05-01), pages 203 - 11 |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012152514A1 (fr) | 2011-05-11 | 2012-11-15 | Ldiamon As | Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine |
| RU2499557C1 (ru) * | 2012-10-08 | 2013-11-27 | Арсений Юрьевич Шитов | Способ оценки волюморегулирующей функции почек в условиях повышенного давления газовой среды |
| DE102012112790A1 (de) * | 2012-12-20 | 2014-06-26 | B. Braun Avitum Ag | Verfahren und Vorrichtung zur Bestimmung von Abfallprodukten wie Indoxyl Sulfate in der Dialyse |
| RU2525738C1 (ru) * | 2013-04-09 | 2014-08-20 | Арсений Юрьевич Шитов | Способ оценки кальцийуретической функции почек человека в условиях повышенного давления газовой среды |
| US9423338B2 (en) | 2014-05-08 | 2016-08-23 | B. Braun Avitum Ag | Apparatus and apparatus control method for the quantitative concentration determination of selected substances filtered out of a patient's body in a fluid |
| DE102014106489A1 (de) * | 2014-05-08 | 2015-11-12 | B. Braun Avitum Ag | Vorrichtung und Vorrichtungs-Steuerungsverfahren zur quantitativen Konzentrationsbestimmung ausgewählter aus einem Patientenkörper ausgefilterter Substanzen in einer Flüssigkeit |
| CN105823746A (zh) * | 2016-05-23 | 2016-08-03 | 青岛海大生物集团有限公司 | 一种水溶肥料中壳聚糖含量的检测方法 |
| CN105823746B (zh) * | 2016-05-23 | 2018-08-17 | 青岛海大生物集团有限公司 | 一种水溶肥料中壳聚糖含量的检测方法 |
| US11255844B2 (en) | 2018-03-06 | 2022-02-22 | Fresenius Medical Care Holdings, Inc. | Peritoneal dialysis systems and related methods |
| CN112805044A (zh) * | 2018-08-23 | 2021-05-14 | 尼普洛株式会社 | 细胞外液量计算装置和细胞外液量计算方法 |
| WO2020182395A1 (fr) | 2019-03-11 | 2020-09-17 | Gambro Lundia Ab | Estimation du taux de génération d'une substance chez des patients sous dialyse |
| RU2709469C1 (ru) * | 2019-10-03 | 2019-12-18 | Арсений Юрьевич Шитов | Способ определения степени индивидуальной устойчивости водолазов к токсическому действию азота по показателям функций почек |
| RU2709477C1 (ru) * | 2019-10-03 | 2019-12-18 | Арсений Юрьевич Шитов | Способ определения степени индивидуальной устойчивости водолазов к токсическому действию кислорода по показателям функций почек |
| WO2022172059A1 (fr) * | 2021-02-12 | 2022-08-18 | AusMed Global Limited | Système et procédé de détermination d'une concentration d'un analyte dans un fluide |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2577270A1 (fr) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2577270A1 (fr) | Procédé et dispositif de mesure et de surveillance des concentrations de substances dans un liquide biologique | |
| US20230243752A1 (en) | System and method for monitoring the health of dialysis patients | |
| JP4515786B2 (ja) | 全血中の分析対象物の計測に対するヘマトクリットの影響を減らす方法ならびに当該方法で有用な試験キット及び試験用品 | |
| AU2012241983B2 (en) | Method and apparatus for monitoring a treatment of a patient, preferably for monitoring hemodialysis, hemodiafiltration, and/or peritoneal dialysis | |
| US9423338B2 (en) | Apparatus and apparatus control method for the quantitative concentration determination of selected substances filtered out of a patient's body in a fluid | |
| US8125623B2 (en) | Correlation technique for analysis of clinical condition | |
| EP2861127A1 (fr) | Procédé et dispositif de surveillance d'un traitement extracorporel du sang d'un patient | |
| Jerotskaja et al. | Optical online monitoring of uric acid removal during dialysis | |
| Roth et al. | Infrared spectroscopy in hemodialysis: reagent-free monitoring of patient detoxification by infrared spectroscopy | |
| US9103789B2 (en) | Method and device for determining content of the middle and protein bound uremic toxins in a biological fluid | |
| WO2009071102A1 (fr) | Procédé et dispositif optique pour mesurer des concentrations de substances dans des fluides biologiques | |
| Senftleber et al. | Reversed-phase liquid-chromatographic analysis of hemodialysate from uremic patients. | |
| Fridolin et al. | On-line monitoring of solutes in dialysate using wavelength-dependent absorption of ultraviolet radiation | |
| Lin et al. | Optoelectronic online monitoring system for hemodialysis and its data analysis | |
| Lauri et al. | HPLC study of uremic fluids related to optical dialysis adequacy monitoring | |
| US20240102930A1 (en) | Multiparametric Optical Method and Device for determining Uremic Solutes, including Uremix Toxins, in Biological Fluids | |
| Uhlin et al. | Optical monitoring of dialysis dose | |
| Tomson et al. | Development of a method for optical monitoring of creatinine in the spent dialysate | |
| Kondepati et al. | Infrared transmission spectrometry for the determination of urea in microliter sample volumes of blood plasma dialysates | |
| Lauri et al. | Optical dialysis adequacy monitoring: small uremic toxins and contribution to UV-absorbance studied by HPLC | |
| Holmar et al. | Beta2-microglobulin measurements in the spent dialysate using fluorescence spectra | |
| LAURI | Elimination of Uremic Toxins during Dialysis assessed with the Optical and Analytical Methods | |
| Jerotskaja et al. | Improved optical method for measuring concentration of uric acid removed during dialysis | |
| Lagali et al. | Hemodialysis monitoring in whole blood using transmission and diffuse reflection spectroscopy:<? xpp qa?> a pilot study | |
| Lauri et al. | Optical dialysis adequacy sensor: contribution of chromophores to the ultra violet absorbance in the spent dialysate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11741089 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011741089 Country of ref document: EP |